Media headlines about Celldex Therapeutics (NASDAQ:CLDX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.6983284677107 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Celldex Therapeutics (CLDX) remained flat at $2.46 during trading on Thursday. 2,323,671 shares of the company’s stock traded hands. The firm’s 50 day moving average is $2.42 and its 200 day moving average is $2.94. The firm’s market capitalization is $315.72 million. Celldex Therapeutics has a one year low of $2.20 and a one year high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. Celldex Therapeutics’s revenue was up 175.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.32) earnings per share. On average, equities research analysts forecast that Celldex Therapeutics will post ($1.04) EPS for the current year.

Several analysts have recently weighed in on the stock. Jefferies Group LLC restated a “hold” rating and set a $3.50 price objective (down previously from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, May 11th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Wednesday, May 31st. ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Celldex Therapeutics presently has a consensus rating of “Hold” and an average price target of $7.32.

ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics (CLDX) Getting Somewhat Positive Press Coverage, Report Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.